Antigen-Specific Tolerizing Immunotherapy Promising in Rheumatoid Arthritis
Antigen-specific tolerizing immunotherapy may have therapeutic potential in rheumatoid arthritis.
Antigen-specific tolerizing immunotherapy may have therapeutic potential in rheumatoid arthritis.
Study authors assessed the incidence, time-trends, and outcomes of serious infections in Sjögren syndrome.
Researchers compared the beneficial effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on gout risk in patients with type 2 diabetes.
The long-term safety and efficacy of tocilizumab in patients with systemic sclerosis were assessed in an open-label study.
Researchers assessed thyroid disease risk between the different forms of ANCA-associated vasculitis (AAV), and compared the clinical features of AAV in patients with and without thyroid disease.
Researchers compared and evaluated pharmacologic interventions for the prevention of recurrent miscarriage in women with antiphospholipid syndrome.
The research design of RA BIODAM and study population’s clinical characteristics over 2 years of follow-up were published in an initial report.
Various combinations of genes, environmental factors, and chance may affect early immune activation and symptom onset in rheumatoid arthritis.
Researchers assessed nationally endorsed performance measures for rheumatoid arthritis care using population-based administrative data.
The majority of patients with rheumatoid arthritis-associated bronchiectasis treated with rituximab have a satisfactory safety profile.